Physicians' Academy for Cardiovascular Education

Agenda Topics ▼Video ▼Online-CME News ▼Meeting Reports Slides ▼About

AHA 2018 ▼BET Inhibition ▼CV Inflammation ▼Diabetes & CVD ▼ESC 2018 ▼Expert Meeting GLP-1, CVD & T2DM ▼Invest in your arteries ▼PCSK9 ▼

HoFH

Feb. 8, 2014

Share this page with your colleagues and friends:

Continue reading:

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

Antihypertensive treatment does not result in reduced mortality or CV events in low-risk patients with mild hypertension

Literature - Nov. 9, 2018 - Sheppard JP et al. - JAMA Intern Med 2018

Reduced risk of MACE with PCSK9 inhibitor in patients with ACS

News - Nov. 9, 2018

Novel exercise parameter inversely associated with risk of HF and mortality

Literature - Nov. 5, 2018 - Al Rifai M et al. - Heart 2018

Atherosclerosis

Updated AHA/ACC cholesterol guidelines focus on more personalized risk assessment

News - Nov. 11, 2018

Virtual histology does not reveal PCSK9 inhibition-induced changes in plaque composition

Literature - Oct. 18, 2018 - Nicholls SJ et al. - J Am Coll Cardiol. 2018

Summary | Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

Munich, Berlin - August 25, 2018

Atrial fibrillation

Atrial fibrillation associated with worse long-term CV outcomes in HFmRF and HFpEF

Literature - Oct. 30, 2018 - Zafrir B et al. - Eur Heart J 2018

Population screening for atrial fibrillation with a smartphone

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium

NOAC during AF ablation associated with reduced risk of adverse outcomes

Literature - Sep. 17, 2018 - Kirchhof P et al. - Eur Heart J 2018

CVRM

U-Prevent helps predict individual effect of medication on CVD

News - Oct. 16, 2018

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Challenges and models in CV risk management: Start early, Invest in your arteries

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom

Diabetes

2018 Guidelines on the management of cholesterol: take home messages

News - Nov. 11, 2018

SGLT2 inhibitor treatment may now be considered in broader T2DM population

3' education - Nov. 11, 2018

SGLT2 inhibitor lowers HF hospitalization in both primary and secondary prevention T2DM patients

News - Nov. 11, 2018

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

Familial Hypercholesterolemia

Updated AHA/ACC cholesterol guidelines focus on more personalized risk assessment

News - Nov. 11, 2018

Final phase 3 study of bempedoic acid met safety and tolerability endpoints

News - Oct. 29, 2018

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA

GLP-1 RA & CVD

GLP-1 RA demonstrates superiority in reduction of CV events in T2DM

News - Nov. 7, 2018

Diabetes, Cardiology & Novel therapeutic Approaches: Science, Outcomes and Practice

Agenda - Dec. 6, 2018 - WCC, Dubai, UAE

BP regulation appears central to CV benefit seen with improved glycemic control

Literature - Oct. 25, 2018 - Schwarz PEH et al. - J Am Coll Cardiol 2018

Heart Failure

Initiation of ARNI in patients with acute decompensated heart failure

3' education - Nov. 13, 2018 - Eric Velazquez, MD

It's too early for treatment withdrawal after recovery from dilated cardiomyopathy

3' education - Nov. 12, 2018 - Jane Wilcox, MD

Recovery after dilated cardiomyopathy often means remission rather than cure

News - Nov. 12, 2018

HFpEF: The essentials to know

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA

Slides: HFpEF: What is it & size of the problem

Slides (presentation) - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

Hypertension

Antihypertensive treatment does not result in reduced mortality or CV events in low-risk patients with mild hypertension

Literature - Nov. 9, 2018 - Sheppard JP et al. - JAMA Intern Med 2018

Use of β-blockers in early pregnancy not associated with increased risk of congenital overall or cardiac malformations

Literature - Nov. 1, 2018 - Bateman BT et al. - Annals of Internal Medicine 2018

Periodontitis negatively affects antihypertensive treatment success at high BP

Literature - Oct. 30, 2018 - Pietropaoli D et al. - Hypertension 2018

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Lipids

Reduced all-cause mortality with PCSK9 inhibitor in patients with ACS

News - Nov. 12, 2018

Cholesterol absorption inhibitor prevents atherosclerotic CV events in older patients

News - Nov. 12, 2018

2018 Guidelines on the management of cholesterol: take home messages

News - Nov. 11, 2018

Lp(a)

Apo(a) antisense oligonucleotides safely and effectively reduces Lp(a) in patients with CVD

News - Nov. 11, 2018

Updated AHA/ACC cholesterol guidelines focus on more personalized risk assessment

News - Nov. 11, 2018

High Lp(a) levels associated with increased CV risk despite statin treatment

Literature - Oct. 16, 2018 - Willeit P et al. - The Lancet 2018

PAH - Q&A

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

What is the underlying pathophysiology of PAH and what are its characteristics?

3' education - Jan. 11, 2017 - Bologna, Italy - Nazzareno Galiè, MD

Which clinical PH groups can be distinguished?

3' education - Jan. 10, 2017 - Bologna, Italy - Prof Nazzareno Galiè

PCSK9

Reduced all-cause mortality with PCSK9 inhibitor in patients with ACS

News - Nov. 12, 2018

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

3' education - Nov. 11, 2018

Reduced risk of MACE with PCSK9 inhibitor in patients with ACS

News - Nov. 9, 2018

PCSK9 expert opinions

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Stroke

Antihypertensive treatment does not result in reduced mortality or CV events in low-risk patients with mild hypertension

Literature - Nov. 9, 2018 - Sheppard JP et al. - JAMA Intern Med 2018

Higher healthy diet score is associated with a lower risk of mortality and CV events across the globe

3' education - Aug. 28, 2018 - Dr. Andrew Mente, Hamilton, ONT, Canada

No overall benefit of use of aspirin in primary prevention setting in diabetes patients and individuals with moderate CV risk

News - Aug. 26, 2018

© 2006 - 2018 pace-cme.org - About